The MFU Devices Actually Used in Korea Right Now

I am writing this from a hotel desk in Sinsa-dong on my fourth Gangnam trip, and the brochure pile next to my laptop is bigger than it has ever been. Three years ago, the MFU conversation in this district was basically Ultherapy versus Shurink and a polite mention of Doublo. In 2026 it is not that anymore. Korean manufacturers have launched new generations, the original Merz platform has been re-released as a higher-line variant, and at least two more devices consistently show up on the consultation menu. So I sat down with my coordinator, asked her to walk me through every micro-focused ultrasound platform her clinic and the nearby clinics currently run, and turned my notes into this guide. None of these profiles name a clinic — Korean medical advertising rules prohibit ranking named practices, and the more useful read is the device-by-device one. This is not a winner list. It is a categorical reading of the nine MFU platforms American patients in Gangnam are actually being offered right now, with the honest trade-offs nobody fits into a glossy brochure.

What MFU is, and why the device list keeps growing

Micro-focused ultrasound, or MFU, is a non-invasive lifting modality that delivers focused ultrasound energy below the skin surface to create small thermal coagulation points at selectable depths — typically 1.5mm, 3.0mm, and 4.5mm — which patients report can stimulate a remodeling response over the following months. Every device in this guide works on that broad mechanism. What differs is the transducer engineering, the line-count economics, the visualization layer, and the energy delivery pattern.

The reason the list keeps growing is straightforward. Korean MFDS clearance is faster and more accessible to local manufacturers than U.S. FDA clearance is to American manufacturers, and Gangnam is the densest aesthetic-medicine market on earth. A 2024 review in the Journal of Cosmetic Dermatology on micro-focused ultrasound for facial laxity noted that the published evidence base for MFU as a category is robust, while head-to-head trials between specific platforms remain limited. That is the literature reality, and it shapes every device profile below. The mechanism is well-supported. The platform-versus-platform claims are not, and the categories are real even if the relative ranking is not — because the right device depends on your face, your budget, and the practitioner whose hand is going to be on the transducer.

Featured A — Ultherapy (the original Merz platform)

Ultherapy is the U.S. FDA-cleared MFU device manufactured by Merz Aesthetics, with clearance dates running from 2009 (brow) through 2012 (submentum, neck) and a later clearance for upper-chest fine lines. It is the platform that built the category in the U.S. market, and it is the device most American patients ask for by name when they walk into a Gangnam consultation. The defining technical feature is the real-time visualization screen — the practitioner can actually see the dermal layer the transducer is targeting before she fires, which my Gangnam provider described, in a sentence I have quoted to friends ever since, as "the one where you stop guessing."

In the room, an Ultherapy session typically runs 300 to 600 lines for a full-face protocol, depending on indication and laxity. Cartridges are single-use and run higher per shot than the Korean alternatives — that is the central price-versus-evidence trade-off that defines the platform. American patients tend to weight the FDA paper trail heavily, which is rational on logistical grounds even if the clinical argument for FDA clearance over MFDS clearance is weaker than the marketing implies. I picked Ultherapy on my first trip and stayed with it on my second because the visualization screen mattered to my comfort, not because I could prove a clinical advantage on someone else's face.

The trade-offs are honest. You pay more per session. You get the longest published English-language outcome literature in the category. You get the visualization. You give up the option of running higher line counts in the same session window — because Ultherapy's line-count ceiling is more conservative than the newer Korean platforms designed for high-volume linear delivery. For the patient who values documented clearance and the visualization layer, this is the regimen. For the patient on a tight budget or one who values total line throughput, it is not. Choose accordingly, and choose for your own reasons rather than because Reddit told you so. Studies suggest comparable mechanism across MFU platforms — Ultherapy's specific edge is the documentation and the screen, not a unique mechanism. The other thing worth noting is that most Gangnam clinics that have moved to Ultherapy PRIME still keep the original Ultherapy cartridge available for patients who request it specifically; if you have had Ultherapy before and want continuity with your prior treatment baseline, that option is usually still on the menu.

Featured B — Ultherapy PRIME (the higher-line variant)

Ultherapy PRIME is the next-generation Merz platform that delivers a higher line-count session in the same time window as the original Ultherapy, with refined transducers and a workflow that Korean providers describe as faster pacing without compromising the depth pattern. It is, in 2026, the version of Ultherapy most U.S.-trained practitioners in Gangnam are running for new American patients, and it is what my coordinator quoted on my third trip when I asked whether the platform had changed since my second. The original Ultherapy is still on the menu — some clinics offer both, and pricing varies by cartridge selection — but the centre of gravity has clearly moved toward PRIME for new bookings.

The practical difference, in the room, is throughput. PRIME can run a full-face protocol with materially more total lines in roughly the same forty-five to sixty minutes — meaning the practitioner can extend the depth pattern into more facial sub-zones without lengthening the appointment. That matters more than it sounds. The lower-face and submentum zones are where most of my visible result lives, and a session that allots more lines to those zones without rushing the brow is a session I am willing to pay for. My provider was specific that PRIME does not change the underlying mechanism — same MFU energy, same SMAS targeting at 4.5mm — but the line-count budget is more generous and the cartridge layout is redesigned for slightly faster session pacing.

The published outcome data on PRIME specifically is thinner than on the original Ultherapy, simply because PRIME has been on the market for less time. The mechanism transfer is a reasonable inference, not a proven equivalence. Patients report results comparable to the original platform in the right hands, with a slight preference for PRIME on lower-face and jawline indications because of the line-count headroom. For the American patient who is weighing the original Ultherapy against PRIME at the same clinic, the choice usually reduces to whether the price step matches the line-count step — and on most of the pricing sheets I have seen this trip, it does. The transducer set is also slightly redesigned, which the marketing emphasises and which I cannot independently evaluate. May help is the right framing here, as elsewhere — and if your provider runs both Ultherapy generations, ask her directly which one she would book on her own face today, and why.

Featured C — Shurink Universe (Classys, Korea)

Shurink Universe is the current generation of the Shurink MFU platform manufactured by Classys, the Korean medical device company that has built the most substantial domestic MFU market share over the past five years. KFDA-cleared with a growing international presence, Shurink Universe runs at the same 1.5/3.0/4.5mm depth set as Ultherapy, with a wider linear transducer in the latest cartridge generation that allows higher line counts in the same session window — which is the central operational difference Korean clinicians cite when they discuss the platform.

The practical reading is that Shurink Universe is the platform Korean patients tend to default to, for cost reasons that are real and not subtle. Cartridges run materially lower than Ultherapy, which translates into a session price gap that adds up over a multi-treatment regimen. My coordinator put it directly: "Korean patients pick Shurink because it is comparable in result and lower in price; American patients pick Ultherapy because of FDA recognition. Both are reasonable." That is the honest framing. Shurink Universe lacks the real-time visualization screen — the practitioner is delivering blind to the depth pattern she has selected, which depends more heavily on her training and consistency than the screen-equipped Ultherapy delivery does. For a high-volume operator who runs Shurink every day, that is not a meaningful disadvantage. For an operator running Shurink occasionally, it might be.

The published English-language base on Shurink is smaller than on Ultherapy, but Korean-led publication output has grown materially since 2022 and the body of work is no longer thin. Patients report comparable lifting results in skilled hands, with the platform's higher line-count headroom occasionally producing visible jawline definition that some patients describe as more pronounced than their previous Ultherapy session — though this comparison is confounded by line count, depth pattern, and operator hand, and I would not generalize from anecdote. Studies suggest the mechanism is comparable across MFU platforms; Shurink's specific edge is throughput at lower per-session cost. For the patient who values total lines delivered over visualization layer, this is the regimen. For the patient who values the screen, it is not. A second practical note — Shurink Universe sessions tend to run slightly faster than Ultherapy at the same line count, partly because the wider cartridge covers more area per pass, which matters for patients on tight trip windows.

Featured D — Doublo Gold (Hironic, Korea)

Doublo Gold is the iteration of the Doublo MFU platform manufactured by Hironic, KFDA-cleared and present in Korean dermatology and aesthetic clinics with a market share that has expanded steadily over the past several years without quite reaching the volume of Shurink. The depth set is the same 1.5/3.0/4.5mm; the transducer count and per-line cost structure differ from both Ultherapy and Shurink, and the platform is most often quoted on Korean clinic pricing sheets as a value-tier alternative within the MFU category.

The practical positioning is honest. Doublo Gold is not trying to be the FDA-clearance platform or the highest-throughput platform — it is competing on per-session price within a small but real segment of Korean clinics that have built operator experience on the Hironic energy curve. My coordinator was specific that the platform's results, in skilled hands, are comparable to Shurink at a slightly lower price point, but that the price gap to Shurink is narrower than the marketing implies once you compare matched line counts. A friend who flew in from Vancouver chose Doublo on her first trip because her clinic ran a package she trusted; she reported a comparable lifting result to my contemporaneous Ultherapy session at a meaningfully lower cost. One data point, two different faces — I am not drawing a conclusion from that. I am telling you what I saw.

The published English-language outcome literature on Doublo specifically is the thinnest of the three flagship Korean MFU platforms, in my reading. That is not the same as saying it does not work. It is saying that if you are the kind of patient who reads the literature before booking — and I am, sometimes to my own annoyance — you will find less material to read. Operator experience may matter more than literature volume for any of the three Korean MFU devices, and Doublo's center of gravity tends to live in clinics where the operator has chosen to invest deeply in the Hironic platform rather than rotate across multiple devices. That kind of platform-concentration is, in my reading, more predictive of outcome than the brand label is.

Featured E — Ultraformer III / MPT (Classys, Korea)

Ultraformer III, with its current MPT (Multiple Points Technology) iteration, is the second major Classys MFU platform — sitting alongside the Shurink line and serving a slightly different operator preference within the Korean clinic market. KFDA-cleared and exported to several international markets, Ultraformer covers the standard 1.5/3.0/4.5mm depth set plus a 2.0mm option that some practitioners use for the dermal-mid layer, and the MPT cartridge delivers multiple thermal coagulation points per shot rather than a single point, which is the platform's main technical differentiator in the room. The two-platform Classys footprint — Shurink Universe and Ultraformer III — sometimes confuses American patients who assume the manufacturer would consolidate; my coordinator was specific that the platforms serve different operator workflows and that her clinic runs both, with the choice usually made at the practitioner level rather than the patient level.

The practical effect of the multiple-points cartridge is throughput density. A session can deliver more total points in the same line count, which Korean operators describe as a way to extend coverage into transition zones — the temple-to-cheek edge, the jawline-to-neck transition — without burning through the line-count budget on those zones. Whether that translates into a visible result advantage is platform-specific and operator-specific; my reading of the available material is that it produces more uniform coverage at the price of slightly less per-point energy, which is the sort of trade-off that may help some indications and is neutral on others. Patients report the result feels comparable to Shurink Universe in skilled hands.

Ultraformer III tends to show up in clinics that have built workflows around faster session pacing and broader-coverage protocols rather than the high-precision depth-pattern delivery that Ultherapy is known for. The platform's published evidence base is moderate — larger than Doublo's, smaller than Ultherapy's — and the international presence is real but uneven. For patients who are weighing Shurink Universe against Ultraformer at the same Classys-aligned clinic, the practical question is operator preference: which platform does the practitioner run more often, and which does she trust her own hand on. That answer matters more than the cartridge architecture does. Studies suggest the lifting effect is comparable; the differentiator is the practitioner's familiarity, which is often platform-loyal in this segment of the market — and not something the brochure will tell you.

Featured F — Liftera (Classys, Korea — linear transducer focus)

Liftera is the third Classys-developed MFU device in Korean clinics, designed around a linear transducer architecture that delivers a continuous line of focused ultrasound energy rather than the discrete-point pattern that defines Ultherapy and the standard Shurink cartridges. KFDA-cleared with a meaningful Korean clinic presence, Liftera positions itself as a faster, broader-coverage alternative within the MFU category, with a session pacing that some operators find more efficient for the lower-face and neck zones specifically. The platform also has a slightly different cartridge cost structure that has made it attractive for clinics building maintenance-oriented packages.

The technical conversation around linear-transducer MFU is interesting, and a touch unsettled. The argument for the linear pattern is more uniform thermal delivery across a treatment line, which may produce smoother coverage in zones where discrete-point patterning can leave perceptible gaps. The argument against is that the energy density per unit length is lower than the discrete-point platforms deliver, which may shift the result curve toward gentler tightening rather than the more pronounced lifting that high-energy discrete-point sessions can produce. Patients report mixed comparative experiences, and I would read the literature carefully before forming a strong view. The honest answer, as far as I can tell, is that linear-transducer MFU is a different shape of energy delivery rather than a strictly better or worse one.

Liftera tends to show up in Korean clinic protocols as a complementary platform — paired with discrete-point MFU on the same patient over a series of sessions, or used for maintenance on patients whose primary lifting has already been delivered. For the American patient considering Liftera as a primary lifting device, my honest read is to ask the practitioner specifically about her case volume on Liftera versus Shurink or Ultherapy, and to weight that case-volume answer heavily. The platform is real, the mechanism is supported, and the outcome quality depends, as it does for every device in this list, on the operator's hand more than the brochure claim. May help is the right framing — Liftera is an option in the menu, not the obvious first choice for every face, and the patients who report the best Liftera experiences tend to be the ones using it as a complementary or maintenance tool rather than as a primary lifting platform.

Featured G — Sofwave (Sofwave Medical, US-based, Israeli technology)

Sofwave is a US-cleared (FDA), Israeli-developed device that uses synchronous ultrasound parallel beam technology — a different ultrasound architecture from the discrete-point MFU that defines the rest of this list. The depth target is fixed at approximately 1.5mm, which is shallower than the SMAS-targeting 4.5mm of traditional MFU, and the indication is dermal collagen remodeling rather than deeper SMAS lifting. The device has FDA clearance for improving facial lines and lifting brow, submentum, and neck, and it has built a meaningful U.S. market presence over the past three years that has begun translating into Korean clinic adoption since 2024.

Sofwave is a different category, even though it appears in the same MFU conversation in Korean clinics. The patients who pick Sofwave are usually the ones who do not want the deeper-tissue thermal coagulation that traditional MFU delivers, and who are weighing fine-line dermal tightening against a more pronounced lifting effect. In Gangnam clinics that offer both, my coordinator described Sofwave as the option for patients with mild surface laxity and good underlying structure, and traditional MFU as the option for patients with moderate SMAS-layer descent. That is a reasonable framing, and one I have heard echoed across at least three coordinators on this trip.

The trade-offs are worth knowing. Sofwave sessions are generally shorter and the discomfort profile is, in patient reports, milder than Ultherapy at the deeper passes — though the dermal-only depth target means it is not addressing the same anatomical layer. Pricing in Gangnam tends to land between Ultherapy and the value-tier Korean MFU platforms, and the published evidence base is growing but smaller than for Ultherapy. For the patient with mild laxity and a preference for FDA-cleared, US/Israeli-engineered platforms, this is a defensible choice. For the patient with moderate SMAS descent, it is probably not the first device to book — though some Gangnam protocols pair Sofwave with deeper MFU for patients who want both layers addressed in a single trip. Studies suggest Sofwave's mechanism is supported in its target depth; the question is whether the target depth matches your indication, and that question deserves an honest answer in consultation rather than a marketing one.

Featured H — V-RO (newer Korean MFU entrant)

V-RO is one of the newer Korean MFU platforms to enter the Gangnam clinic conversation in earnest — KFDA-cleared, with a transducer architecture and depth set in line with the established 1.5/3.0/4.5mm category standard, and a market entry strategy aimed at clinics that want a Shurink-comparable platform at a slightly lower cartridge cost. The platform is not on every consultation menu yet, but it has appeared on three of the four pricing sheets I reviewed on this trip, which is more presence than it had a year ago. I am including it here because the trajectory matters even when the current case volume is moderate.

The practical positioning is value-tier within the Korean MFU segment, with claims around energy stability and cartridge longevity that are typical of newer entrants. My coordinator was honest that V-RO is a platform her clinic has begun running for budget-conscious patients but does not yet recommend over Shurink for moderate-to-significant lifting indications, on grounds of operator familiarity and the comparatively thin published outcome data. That kind of honesty from a coordinator is rare and worth taking seriously. New platforms in this category tend to require eighteen to thirty-six months of clinic-floor running before the operator hand is consistent enough to recommend at the level of the established Korean MFU platforms, and V-RO is currently in the middle of that maturation window.

The trade-offs are familiar. Lower per-session cost, less operator track record, less published data, and a result curve that may be comparable to Shurink in skilled hands but is harder to predict at the level of confidence the established platforms support. For the patient who values cost above all and is willing to accept that confidence trade-off, V-RO is a reasonable option in 2026. For the patient who wants the most predictable result, the established Shurink Universe or Ultherapy lines are still the better-evidenced choices. The right time to add V-RO to your shortlist is probably when your clinic's case volume on the platform reaches a threshold the practitioner herself describes as confident — and it is fair to ask that question directly, and to listen to whether the answer carries the same conviction her answer about Shurink or Ultherapy does.

Featured I — Tensage / linear-FU platforms (the maintenance-tier category)

Tensage and the broader category of linear focused-ultrasound platforms occupy the maintenance tier of the Korean MFU market — gentler energy delivery, shorter sessions, and a positioning that is explicitly maintenance-oriented rather than primary-lifting-oriented. KFDA-cleared platforms in this category have grown in clinic adoption since 2023, particularly for patients who have already had a primary MFU session and are looking to extend the result curve at six- to twelve-month intervals without committing to a full-pass session. The category is not always labeled "MFU" on the pricing sheet; sometimes it shows up as "lifting maintenance" or "focused ultrasound touch-up," and the underlying technology overlaps with the discrete-point platforms above without quite reaching their energy density.

The practical use case is real and worth understanding. After a full Ultherapy or Shurink Universe session, the result peaks around two to three months, gradually softens over the following twelve to eighteen months, and the conventional advice is a touch-up session at twelve to fifteen months. The maintenance-tier platforms compress that touch-up into a thirty-minute session at a lower cost, with the trade-off that the touch-up does not deliver the same total lifting effect a full primary session does. That is reasonable. It is the dental-cleaning model of MFU — frequent, light, and additive — versus the annual deep-restorative model, and patients who plan their facial regimen across several years tend to find this rhythm sustainable.

For patients who have committed to a multi-year regimen, the maintenance tier is increasingly part of the conversation in Gangnam clinics. The category is not the right entry point for a first-time MFU patient. It is the right entry point for a returning patient who wants to extend her primary-session result curve without the price and time commitment of another full session. My coordinator runs maintenance on her own face roughly every nine months on a Tensage-class platform, and described it as "the way I keep the line where it was after my last full session." That is a frame worth borrowing if you are planning a multi-year approach. Patients report the maintenance sessions are gentler in discomfort and shorter in downtime than the primary platforms, with a result curve that is additive rather than transformational. That is the honest read, and it is the read that has begun to shift my own thinking about how to plan trips three and four around lighter-touch sessions rather than a full primary every time.

Side-by-side: nine MFU platforms in 2026

The matrix below is categorical — it identifies operational shape, not relative performance, and the cells should be read as descriptive rather than as a ranking. Pricing tier is left intentionally rough because cartridge counts and clinic packages shift the per-session number more than the platform label does. The right device is the one that fits your face, your budget, your tolerance for visualized versus blind delivery, and the practitioner whose hand is going to be on the transducer. Anyone telling you otherwise is selling the brochure.

How I would actually pick one in 2026

If you have not consulted yet, do not pick the device first. Pick the practitioner first, and then ask which device on her menu she runs the most. Operator hand on a familiar platform beats operator hand on a less-familiar platform almost every time.

For the first-time American patient with FDA-clearance preference, Ultherapy or Ultherapy PRIME are the defensible defaults. For the budget-aware patient with moderate laxity who trusts the practitioner's case volume on Korean MFU, Shurink Universe is a reasonable choice; Doublo Gold or V-RO can be considered if the price gap is meaningful and operator confidence is real. For mild dermal-only laxity, Sofwave is a category-different option worth weighing. For patients in a multi-year regimen, the maintenance tier is the right tool at twelve to fifteen months out from a primary session.

Line count is not a quality marker. A 600-line session can produce a worse result than a 400-line session in a different operator's hands. Ask your practitioner what depth pattern she will run, why, and how she chose the line count for your indication. The answers will tell you more than the device label on the cartridge.

Editorial note on hedging, sources, and what this guide is not

This piece is editorial reading, not clinical recommendation, and the device profiles above describe categorical positioning rather than nominate any specific clinic. Korean medical advertising rules (article 56 paragraph 4 of the Medical Service Act) prohibit comparative ranking of named medical institutions, and an editorial responsibility runs in the same direction. I have written this from the perspective of a returning American patient on her fourth Gangnam trip, with notes from coordinator conversations, manufacturer technical sheets, and the English-language MFU literature available as of 2026. Studies suggest the broad mechanism of MFU is well-supported; direct head-to-head trials of the specific platforms remain limited. May help is the right framing for any device-specific claim — and the best decision on consultation day is the one that respects your face, your budget, and the practitioner's actual hand on her primary platform.

“Pick the practitioner first, then ask which device on her menu she runs the most. Operator hand on a familiar platform beats operator hand on a less-familiar platform almost every time.”

Section: How I would actually pick one in 2026

Frequently asked questions

What does MFU actually stand for, and how is it different from HIFU?

MFU is micro-focused ultrasound — a category of non-invasive lifting devices delivering focused ultrasound energy at selectable depths (typically 1.5mm, 3.0mm, 4.5mm) to create precise thermal coagulation points. HIFU stands for high-intensity focused ultrasound and is a broader category that includes oncology devices. Korean clinics often use the terms interchangeably for aesthetic devices; U.S. regulatory and clinical literature treats MFU as the precise term for the lifting category in this guide.

Is FDA clearance important if I am being treated in Korea?

Practically rather than clinically, yes. FDA-cleared devices in this guide (Ultherapy, Ultherapy PRIME, Sofwave) carry a paper trail that reduces conversation friction with U.S. providers and any future follow-up questions at home. The clinical argument for FDA clearance over KFDA clearance is weaker than the marketing implies; many Korean MFU platforms have substantial published outcome data. Choose on logistics if logistics matter to you, on practitioner-platform fit if they do not.

How do I know if a clinic's operator has enough experience on a specific MFU device?

Ask directly. On consultation day: what is your case volume on this platform in the last twelve months, and what percentage of your MFU cases run on this device. A practitioner running a device sixty percent or more of her cases is platform-loyal, which usually correlates with consistent operator hand. Under twenty percent is less likely to deliver the same consistency, regardless of device quality. The answer is more predictive than the brochure.

What is the difference between Shurink and Shurink Universe?

Shurink Universe is the current generation of the Classys MFU platform, with redesigned transducers, a wider linear cartridge that allows higher line counts in the same session window, and refined energy stability relative to the original Shurink. Most Gangnam clinics have moved fully to Shurink Universe by 2026; some still offer the original at a slightly lower price for maintenance sessions. The Universe generation is what most coordinators will quote unless you ask specifically.

Which MFU device hurts the least?

Pain is platform-related but more strongly operator-related and patient-related. Discomfort is generally more pronounced on the deeper passes (4.5mm SMAS targeting) regardless of device, and milder on dermal-only or maintenance-tier platforms (Sofwave, Tensage, Liftera). Numbing protocols, line count, and operator pacing change the experience more than the platform label. Patients report Ultherapy and Shurink Universe as most pronounced during the SMAS pass — though either can be made comfortable with adequate numbing and a deliberate operator.

How long do MFU results last, across these devices?

Patients report the result peaks around two to three months, gradually softens over the following twelve to eighteen months, and that a touch-up session at twelve to fifteen months extends the result curve. Literature supports comparable result duration across MFU platforms in skilled hands; head-to-head duration studies are limited. The result curve is more strongly influenced by baseline laxity, line count, depth pattern, and the patient's own collagen biology than by which device was used.

Can I combine MFU devices in the same trip or year?

It is increasingly common in Korean clinic protocols — pairing a primary discrete-point session (Ultherapy, Shurink Universe) with a maintenance-tier or linear platform (Liftera, Tensage) at six- to nine-month intervals. Combining two primary discrete-point platforms in the same trip is generally not recommended; the SMAS layer benefits from healing time between sessions. Ask the practitioner whether her protocol pairs platforms or runs a single platform across the regimen — both are defensible.

Why does this guide refuse to name a winner?

Because the question is malformed. There is no universally superior MFU device — the right device depends on the patient's face, budget, tolerance for visualized versus blind delivery, and the practitioner's platform familiarity. The naming-a-winner framing also conflicts with Korean medical advertising rules. Studies suggest the mechanism is comparable across platforms; what differentiates outcomes is the operator's hand, the depth pattern, and the patient match — none of which a brand label captures.

What questions should I bring into the consultation about MFU device choice?

Five tend to be most useful. One, what is your case volume on each MFU platform in the last twelve months. Two, which depth pattern will you run on my indication, and why. Three, what line count are you proposing, and how was that number chosen. Four, is the platform you are recommending the one you would run on yourself or a close family member. Five, what is your honest read on the price-versus-evidence trade-off versus the next-tier option. The answers surface the practitioner's reasoning more reliably than any brochure.